Adverse events associated with the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis

American Journal of Therapeutics

Volumn 23, Issue 2, 2016, Pages e521-e530

  Wu, Shanshan ^a   Zhang, Yuelun ^a   Sun, Feng ^a   Chen, Mingting ^b   Zhou, Lin ^b   Wang, Ni ^b   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

adverse events; MDR TB; meta analysis; tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADVERSE OUTCOME; ARTHRALGIA; CENTRAL NERVOUS SYSTEM DISEASE; DRUG SAFETY; FREQUENCY; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPOKALEMIA; HYPOTHYROIDISM; INCIDENCE; KIDNEY DYSFUNCTION; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; MENTAL DISEASE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; OTOTOXICITY; PATIENT HISTORY OF THERAPY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL IMPAIRMENT; FACTUAL DATABASE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DATABASES, FACTUAL; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84888212375     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/01.mjt.0000433951.09030.5a     Document Type: Review

References (29)

1. WHO. Global Tuberculosis Control: WHO Report 2012. WHO Document WHO/CDS/TB, Geneva, Switzerland; 2012
2. WHO. Multidrug-Resistant Tuberculosis (MDR-TB): 2012 Update. WHO Document WHO/CDS/TB, Geneva, Switzerland; 2012
3. Tabarsi P, Baghaei P, Jalali S, et al. Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases?. A clinical descriptive study. Scand J Infect Dis. 2009; 41: 10-13
4. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004; 363: 474-481
5. WHO. Guidelines for the Programmatic Management of Drug- Resistant Tuberculosis: 2011 Updated. WHO/HTM/TB, Geneva, Switzerland; 2011
6. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther. 2011; 18: e29-e34
7. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010; 14: 275-281
8. Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first- And second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012; 16: 961-966
9. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005; 9: 1373-137
10. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001; 5: 648-655
11. American Thoracic Society, Centers for Disease Control and Prevention (CDC), Infectious Diseases Society. Treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167: 603-662
12. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005; 365: 318-326
13. Jacob V, Robert L, Lebrun C, et al. Multidrug-resistant tuberculosis: a review of the 23 cases treated by the Saint- Pierre University Hospital (Brussels). Acta Clin Belg. 2009; 64: 113-119
14. Kvasnovsky CL, Cegielski JP, Erasmus R, et al. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011; 57: 146-152
15. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012; 7: e40781
16. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and metaanalysis. Int J Tuberc Lung Dis. 2012; 16: 447-454
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Int J Surg. 2010; 8: 336-341
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-Analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-2012
19. Egger M, Davey Smith G, Schneider M. Systematic reviews of observational studies. In: Egger M, Davey Smith G, Altman D, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London, United Kingdom: BMJ Books; 2002: 211-227
20. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010; 14: 1374-1381
21. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-Analysis. Lancet Infect Dis. 2009; 9: 153-161
22. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174: 935-952
23. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008; 372: 1403-1409
24. Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis. 2008; 12: 750-755
25. Uffredi ML, Truffot-Pernot C, Dautzenberg B, et al. An intervention programme for the management of multidrug- resistant tuberculosis in France. Int J Antimicrob Agents. 2007; 29: 434-439
26. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003; 124: 1476-1481
27. Palmero DJ, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis. 2004; 8: 778-784
28. Kim HJ, Hong YP, Kim SJ, et al. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis. 2001; 5: 1129-1136
29. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009; 4: e7186